---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-24-001736"
form_type: "8-K"
ticker: "LFWD"
cik: "0001607962"
company_name: "Lifeward Ltd."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:09:29.025155+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ReWalk Robotics Q1 2024 revenue surges 340% to $5.3 million, Medicare reimbursement drives growth

## Summary
- Q1 2024 revenue of $5.3 million, up 340% from $1.2 million in Q1 2023.
- Medicare payment for ReWalk Personal Exoskeleton established; MACs approve 14 claims since fee schedule.
- Net loss widened to $6.3 million ($0.73 per share) from $4.3 million ($0.51 per share) in prior year.
- Cash and equivalents of $20.7 million with no debt; full-year 2024 revenue guidance unchanged at $28-$32 million.
- Gross margin declined to 26.4% from 46.4%, impacted by AlterG integration and low product volumes.

## SEC filing metadata
- accession: 0001178913-24-001736
- form_type: 8-K
- ticker: LFWD
- cik: 0001607962
- company_name: Lifeward Ltd.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607962/000117891324001736/0001178913-24-001736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607962/000117891324001736/zk2431465.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-24-001736
- JSON: https://secwatch.observer/filing/0001178913-24-001736.json
- Plain text: https://secwatch.observer/filing/0001178913-24-001736.txt

## Key facts
- Earnings Releases
  Lifeward Ltd. reported the three months ended March 31, 2024 results: revenue $5.3 million, net income Net loss was $6.3 million, or $0.73 per share, EPS $0.73 per share. Guidance reaffirmed.
  - Period: the three months ended March 31, 2024
  - Revenue: $5.3 million
  - Net income: Net loss was $6.3 million, or $0.73 per share
  - EPS: $0.73 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: MACs will enable us to further our mission of broader access to innovative exoskeleton technology for appropriate individuals.” First Quarter 2024 Financial Results Revenue was $5.3 million in the first quarter of 2024, compared to $1.2 million during the first quarter of 2023, up $4.1 million, or 340%. Revenue from the sale of products from the former ReWalk
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607962/000117891324001736/0001178913-24-001736-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.